Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic leukemia (CLL). ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator’s choice of idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in patients with relapsed/refrac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghia, Paolo, Pluta, Andrzej, Wach, Małgorzata, Lysak, Daniel, Šimkovič, Martin, Kriachok, Iryna, Illés, Árpád, de la Serna, Javier, Dolan, Sean, Campbell, Philip, Musuraca, Gerardo, Jacob, Abraham, Avery, Eric J., Lee, Jae Hoon, Usenko, Ganna, Wang, Min Hui, Yu, Ting, Jurczak, Wojciech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666115/
https://www.ncbi.nlm.nih.gov/pubmed/36398134
http://dx.doi.org/10.1097/HS9.0000000000000801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666115/
https://www.ncbi.nlm.nih.gov/pubmed/36398134
http://dx.doi.org/10.1097/HS9.0000000000000801

Ejemplares similares